Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.

Three discontinued the trial in the intervention arm, compared with one in the placebo arm. Bachelez and colleagues have reported their phase II placebo-controlled trial of intravenous spesolimab, an anti-interleukin (IL)-36 receptor monoclonal antibody, in generalized pustular psoriasis (GPP).[1] Fifty-three patients (aged 18-75 years, 68% female, 51% Asian) with a moderate-to-severe GPP flare were enrolled in the 1-week trial. A greater proportion of the spesolimab-treated group achieved GPPGA pustulation score 0 compared with those receiving placebo (54% vs. 6%, I P i < 0-001) and GPPGA clear or almost clear (43% vs. 11%, I P i = 0-02) at 1 week. [Extracted from the article]